Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome
| Autor: | Johannes G. M. Burgerhof, Annie Visser, Nishath Hamza, Cees G. M. Kallenberg, Wayel H. Abdulahad, Rodney P. E. Pollard, Frans G. M. Kroese, Minke G. Huitema, Hendrika Bootsma, Fred K. L. Spijkervet, Jiska Meijer, Arjan Vissink |
|---|---|
| Přispěvatelé: | Personalized Healthcare Technology (PHT), Translational Immunology Groningen (TRIGR), Life Course Epidemiology (LCE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Science in Healthy Ageing & healthcaRE (SHARE) |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Murine-Derived
medicine.medical_specialty Immunology Tumor Necrosis Factor Ligand Superfamily Member 13 Enzyme-Linked Immunosorbent Assay Placebo Gastroenterology General Biochemistry Genetics and Molecular Biology Antibodies Antibodies Monoclonal Murine-Derived Rheumatology Double-Blind Method Internal medicine Monoclonal B-Cell Activating Factor medicine Immunology and Allergy Humans B-cell activating factor GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) B cell biology business.industry CELL-ACTIVATING FACTOR TREATED PATIENTS stomatognathic diseases Endocrinology medicine.anatomical_structure Sjogren's Syndrome Antirheumatic Agents ComputingMethodologies_DOCUMENTANDTEXTPROCESSING biology.protein Prednisolone Rituximab Premedication Antibody business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases, 72(1), 146-8. BMJ PUBLISHING GROUP Annals of the Rheumatic Diseases, 72(1), 146-148. BMJ PUBLISHING GROUP |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2012-202071 |
| Popis: | B cell depletion therapy with rituximab (RTX; 2 weekly infusions of 1000 mg, premedication: 100 mg prednisolone) in primary Sjogren's syndrome (pSS) patients is effective in reducing subjective and objective symptoms.1 As B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are important cytokines involved in B cell survival and activation, we assessed in pSS patients included in a double-blind, randomised, placebo-controlled trial1 the effects of RTX on serum BAFF and APRIL levels up to 48 weeks after RTX. Serum concentrations of BAFF and APRIL were measured by ELISA using kits from RD median 1277 pg/ml (range 907–3802 pg/ml)) compared with healthy controls (n=10; median 983 pg/ml (range 600–1564 pg/ml)); p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|